InvestorsHub Logo
Followers 16
Posts 84
Boards Moderated 0
Alias Born 05/28/2020

Re: cowtown jay post# 11542

Wednesday, 07/22/2020 12:47:50 PM

Wednesday, July 22, 2020 12:47:50 PM

Post# of 42891
HGEN is very well run

* They have done a great job controlling share dilution.
* They have prevented stock price manipulation by locking up a lot of shares.
* They did a pretty good job adding new shares into the market without a huge sharp price drop (today's drop was not that terrible - knock on wood).
* They do not release news tidbits that fuel widespread speculation.

It seems HGEN will complete the full Phase 3 study and then HGEN will publicly report the results after the data has been fully analyzed.

By contrast, CYDY poorly handled the completion of their Phase 2 M/M trial. The efficacy results will still take 4+ weeks to analyze and now its stock price will be in perpetual limbo (short seller paradise) until the end of August.

I did see Millstone's post yesterday.

For whatever reason, it seems that clinical trial recruitment is always fewer patients/day then what an outsider would think. I'd try to enroll everyone that walks through the door into the trial, but it seems hospitals tend to be much more cautious. You'd think these trial enrollment periods would be much shorter. I understand why some big pharma picks hospital trial sites in Mexico, Brazil, or India where they could finish enrollment quicker.

The HGEN clinical trial location in New Hampshire is a 'token site'. I don't think HGEN will get much action up there.